Provided by Tiger Fintech (Singapore) Pte. Ltd.

MaxCyte Inc

2.02
-0.1300-6.05%
Post-market: 2.050.0300+1.49%19:42 EDT
Volume:387.73K
Turnover:806.17K
Market Cap:214.96M
PE:-5.09
High:2.19
Open:2.19
Low:2.02
Close:2.15
Loading ...

MaxCyte Experiences Shift in Major Holdings by BlackRock

TIPRANKS
·
15 Feb

BlackRock Increases Stake in MaxCyte to 7.66%

TIPRANKS
·
14 Feb

BlackRock Adjusts Holdings in MaxCyte, Inc.

TIPRANKS
·
13 Feb

Craig-Hallum Sticks to Their Buy Rating for MaxCyte (MXCT)

TIPRANKS
·
13 Feb

MaxCyte enters strategic platform license with TG Therapeutics

TIPRANKS
·
12 Feb

MaxCyte Licenses Cell-Engineering Technology to TG Therapeutics

MT Newswires Live
·
12 Feb

BRIEF-Maxcyte Says Enters Strategic Platform License With TG Therapeutics

Reuters
·
12 Feb

MaxCyte Signs Strategic Platform License With TG Therapeutics to Advance Its Autoimmune Cell Therapeutics Programs

THOMSON REUTERS
·
12 Feb

MaxCyte Inc - Enters Strategic Platform License With TG Therapeutics

THOMSON REUTERS
·
12 Feb

MaxCyte, Inc. MaxCyte, Inc. - Mxcr - Strategic Platform License With TG Therapeutics

THOMSON REUTERS
·
12 Feb

MaxCyte Inc - TG Therapeutics Obtains Rights to Use MaxCyte Technology

THOMSON REUTERS
·
12 Feb

MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference

GlobeNewswire
·
07 Feb

MaxCyte Announces Executive Stock Transaction

TIPRANKS
·
31 Jan

Craig-Hallum Gives a Buy Rating to MaxCyte (MXCT)

TIPRANKS
·
30 Jan

MaxCyte acquires SeQure Dx for $4.5M at closing, sees accretion

TIPRANKS
·
30 Jan

MaxCyte Acquires Gene Editing Analytics Company SeQure Dx

MT Newswires Live
·
30 Jan

BRIEF-Maxcyte Buys Sequre Dx For $4.5 Million

Reuters
·
30 Jan

MaxCyte Inc - Pays $4.5 Million for Sequre Dx

THOMSON REUTERS
·
30 Jan

MaxCyte Inc - Additional $2.5 Million Contingent on Revenue Targets

THOMSON REUTERS
·
30 Jan

MaxCyte, Inc. MaxCyte, Inc. - Mxcr - MaxCyte® Acquires Sequre Dx

THOMSON REUTERS
·
30 Jan